TrialESMO open2025

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.

X Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.